What pharma companies need to know about the new PBS Notice of Intent requirements
The Department of Health, Disability and Ageing has announced changes to their PBS Notice of Intent (NOI) process that will impact your […]
Author: admin
Market Access Forum for Pharma Industry Professionals
Attend our Market Access Forum tailored for professionals in the pharmaceutical industry! This event provides a unique platform to network with fellow […]
We’ve joined the National AI Centre’s AI Directory
Exciting news! Pulse Economics is proud to be listed on the National AI Centre’s AI Directory, a platform showcasing Australia’s AI capabilities […]
Future proofing HTA: critical conversations for Australian healthcare
Key challenges and opportunities shaping health technology assessment Next Tuesday’s ISPOR workshop brings together Australia’s leading HTA stakeholders: PBAC members, HTA Review […]
The digital health market access challenge in Australia
What we’re seeing We’ve been working with some remarkable Australian digital health companies lately. These are teams with genuinely impressive clinical evidence […]
Kosi Challenge – March 2025
This weekend, our Pulse Economics team took on the Kosi Challenge, climbing Mt Kosciuszko to shine a light on rare cancers. We’re […]
Keeping pace with PBAC and MSAC key dates
Staying ahead in the pharma and medtech sectors requires a deep understanding of regulatory and advisory timelines, such as those set by […]
Positioning Australia’s life sciences industry for global success
Australia is a leader in niche life science segments with strong global markets, including plasma therapies, hearing implants, and sleep apnoea devices. […]
Free market access strategy advisory for medtech startups
Pulse Economics is offering free 30-minute consultations to help you navigate the complexities of market access and reimbursement in Australia. Gain insights […]
Harnessing Real World Data and Evidence
What’s the Difference Between Real World Data and Real World Evidence? While often used interchangeably, there is clear distinction between the terms […]